TrialDiabetes, obesity & metabolism2026

A 52-Week Efficacy and Safety Study of Teneligliptin, as an Add-On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (TERA305 Study).

Jun Sung Moon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.